Last reviewed · How we verify
Sumatriptan+Promethazine (SPr)
Sumatriptan is a selective serotonin receptor agonist, and Promethazine is an antihistamine and anticholinergic.
Sumatriptan is a selective serotonin receptor agonist, and Promethazine is an antihistamine and anticholinergic. Used for Migraine prevention and treatment, Nausea and vomiting.
At a glance
| Generic name | Sumatriptan+Promethazine (SPr) |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Serotonin receptor agonist, Antihistamine, Anticholinergic |
| Target | 5-HT1B, 5-HT1D |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Sumatriptan works by binding to serotonin receptors, specifically 5-HT1B and 5-HT1D receptors, to induce vasoconstriction and inhibit pro-inflammatory neuropeptide release. Promethazine has antihistaminic and anticholinergic effects, which contribute to its sedative and antiemetic properties.
Approved indications
- Migraine prevention and treatment
- Nausea and vomiting
Common side effects
- Dizziness
- Headache
- Nausea
- Somnolence
- Dry mouth
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |